REDISCOVER guidelines for borderline-resectable and locally advanced pancreatic cancer: management algorithm, unanswered questions, and future perspectives

Boggi, U; Kauffmann, EF; Napoli, N; Barreto, SG; Besselink, MG; Fusai, GK; Hackert, T; Hilal, MA; Marchegiani, G; Salvia, R; Shrikhande, SV; Truty, M; Werner, J; Wolfgang, C; Bannone, E; Capretti, G; Cattelani, A; Coppola, A; Cucchetti, A; De Sio, D; Di Dato, A; Di Meo, G; Fiorillo, C; Gianfaldoni, C; Hidalgo Salinas, C

Journal article

REDISCOVER guidelines for borderline-resectable and locally advanced pancreatic cancer: management algorithm, unanswered questions, and future perspectives

Abstract:: The REDISCOVER guidelines present 34 recommendations for the selection and perioperative care of borderline-resectable (BR-PDAC) and locally advanced ductal adenocarcinoma of the pancreas (LA-PDAC). These guidelines represent a significant shift from previous approaches, prioritizing tumor biology over anatomical features as the primary indication for resection. Condensed herein, they provide a practical management algorithm for clinical practice. However, the guidelines also highlight the need to redefine LA-PDAC to align with modern treatment strategies and to solve some contradictions within the current definition, such as grouping "difficult" and "impossible" to resect tumors together. Furthermore, the REDISCOVER guidelines highlight several areas requiring urgent research. These include the resection of the superior mesenteric artery, the management strategies for patients with LA-PDAC who are fit for surgery but unable to receive multi-agent neoadjuvant chemotherapy, the approach to patients with LA-PDAC who are fit for surgery but demonstrate high serum Ca 19.9 levels even after neoadjuvant treatment, and the optimal timing and number of chemotherapy cycles prior to surgery. Additionally, the role of primary chemoradiotherapy versus chemotherapy alone in LA-PDAC, the timing of surgical resection post-neoadjuvant/primary chemoradiotherapy, the efficacy of ablation therapies, and the management of oligometastasis in patients with LA-PDAC warrant investigation. Given the limited evidence for many issues, refining existing management strategies is imperative. The establishment of the REDISCOVER registry (https://rediscover.unipi.it/) offers promise of a unified research platform to advance understanding and improve the management of BR-PDAC and LA-PDAC.

Publication status:: Published

Peer review status:: Peer reviewed

Actions

Email

Email this record

Send the bibliographic details of this record to your email address.

Your Email
Please enter the email address that the record information will be sent to.

-
Your message (optional)
Please add any additional information to be included within the email.
Cite

Cite this record

APA Style

Boggi, U., Kauffmann, E. F., Napoli, N., Barreto, S. G., Besselink, M. G., Fusai, G. K., Hackert, T., Hilal, M. A., Marchegiani, G., Salvia, R., Shrikhande, S. V., Truty, M., Werner, J., Wolfgang, C., Bannone, E., Capretti, G., Cattelani, A., Coppola, A., Cucchetti, A., … Hidalgo Salinas, C. (2024). REDISCOVER guidelines for borderline-resectable and locally advanced pancreatic cancer: management algorithm, unanswered questions, and future perspectives. Updates in Surgery, 76(5), 1573–1591.

MLA Style

Boggi, U., et al. “REDISCOVER Guidelines for Borderline-Resectable and Locally Advanced Pancreatic Cancer: Management Algorithm, Unanswered Questions, and Future Perspectives.” Updates in Surgery, vol. 76, no. 5, Springer, 2024, pp. 1573–91.

Chicago Style

Boggi, U, EF Kauffmann, N Napoli, SG Barreto, MG Besselink, GK Fusai, T Hackert, et al. 2024. “REDISCOVER Guidelines for Borderline-Resectable and Locally Advanced Pancreatic Cancer: Management Algorithm, Unanswered Questions, and Future Perspectives.” Updates in Surgery 76 (5): 1573–91.
Share
Print